|
2024
|
Invention
|
Deuterated compounds. The present disclosure provides deuterated compounds and their use as agoni... |
|
2023
|
Invention
|
Sars-cov-2 mpro inhibitors and uses thereof. This application relates to novel compounds and thei... |
|
|
Invention
|
Crystalline forms and salts of a muscarinic receptor agonist. This invention relates to compounds... |
|
|
Invention
|
1,2-substituted 3-oxopyrazolidine derivatives as prostaglandin e2 receptor 4 (ep4) agonists for t... |
|
|
Invention
|
Pyrrolidine-2-carboxamide derivatives as prostaglandin e2 receptor 4 (ep4) agonists for the treat... |
|
|
Invention
|
Morpholine-3-carboxamide derivatives as prostaglandin e2 receptor 4 (ep4) agonists for the treatm... |
|
|
Invention
|
Anti-par2 antibodies. The present disclosure provides antibodies and antigen-binding fragments ca... |
|
2022
|
Invention
|
Gpr52 modulator compounds. The disclosures herein relate to novel compounds of Formula (1a) or (1... |
|
|
Invention
|
Gpr35 agonist compounds. The disclosures herein relate to novel compounds of formula (1): (1) and... |
|
|
Invention
|
Sars-cov-2 mpro inhibitor compounds. The invention described herein relates to compounds of Formu... |
|
|
Invention
|
Pharmaceutical composition for the treatment of alzheimer's disease or dementia. 14144 receptors,... |
|
2021
|
Invention
|
Pharmaceutical compounds. This invention relates to compounds that are agonists of the muscarinic... |
|
|
Invention
|
Sars-cov-2 mpro inhibitor compounds. P33613WO1 93 ABSTRACT The disclosures herein relate to compo... |
|
|
Invention
|
H4 antagonist compounds. The disclosures herein relate to novel compounds of formula (1): and sal... |
|
|
Invention
|
Cyclic apelin receptor agonists. The disclosures herein relate to novel compounds of formula (1) ... |
|
|
Invention
|
Linear apelin receptor agonists. The disclosures herein relate to novel compounds of formula (1):... |
|
|
Invention
|
Gpr52 modulator compounds. The disclosures herein relate to novel compounds of Formula (1): or a ... |
|
|
Invention
|
Glp-1 receptor antagonists. The disclosures herein relate to novel internally cyclic peptide comp... |
|
|
Invention
|
H4 antagonist compounds. The disclosure herein relates to azetidinylpyrimidin-2-amine derivatives... |
|
|
Invention
|
Glp receptor agonists. The disclosures herein relate to novel compounds of formula (1 ): and salt... |
|
|
Invention
|
Oral glp receptor agonists. The disclosures herein relate to novel compounds of formula (1a) or f... |
|
|
Invention
|
Gpr52 modulator compounds. The disclosures herein relate to novel compounds of Formula (1): and s... |
|
2020
|
Invention
|
Gpr52 modulator compounds. The disclosures herein relate to novel compounds of Formula (1): (1) a... |
|
|
Invention
|
4 receptor antagonist compounds. The disclosures herein relate to novel compounds of formula (1):... |
|
|
Invention
|
Cgrp antagonist compounds. The disclosures herein relate to novel compounds of Formula (1a): and ... |
|
|
Invention
|
Cgrp antagonist compounds. The disclosures herein relate to novel compounds of Formula (1): and s... |
|
|
Invention
|
Orexin 1 receptor antagonists. 123455 are defined herein, and their use in treating, preventing, ... |
|
2019
|
Invention
|
Orexin 1 receptor antagonists. 12344 are defined herein, and their use in treating, preventing, a... |
|
|
Invention
|
Quinolinone and benzoxazine derivatives as muscarinic m1 and/or m4 receptor agonists. 114 144 rec... |
|
|
Invention
|
Bicyclic aza compounds as muscarinic m1 and/or m4 receptor agonists. 1 4144 receptors. Also provi... |
|
|
Invention
|
Pyrazole derivatives as h4 antagonist compounds. The disclosures herein relate to novel compounds... |
|
|
Invention
|
Cyclohexapeptides as selective somatostatin sst5 receptor agonists. The disclosures herein relate... |
|
|
Invention
|
Glp-1 receptor antagonists. The disclosures herein relate to novel compounds of formula (1): and ... |
|
|
Invention
|
Oxadiazoles as agonists of the muscarinic m1 and/or m4 receptor. 14144 receptors. Also provided a... |
|
|
Invention
|
Bridged compounds as agonists of the muscarinic m1 and/or m4 receptor. 14144 receptors. Also prov... |
|
2018
|
Invention
|
Ox1 antagonists.
The disclosures herein relate to novel compounds of formula (1) and salts there... |
|
|
Invention
|
1 antagonists. 123456788 are defined herein, and their use in treating, preventing, ameliorating,... |
|
|
Invention
|
Cgrp receptor antagonists. The disclosures herein relate to novel compounds of formula (IA) where... |
|
2017
|
Invention
|
Heterocyclic compounds having activity as modulators of muscarinic m1 and/or m4 receptors in the ... |
|
|
Invention
|
Inhibitors of protease-activated receptor-2. The present application relates to certain substitut... |
|
|
Invention
|
G proteins. The invention provides a mutant of a parent heterotrimeric G protein alpha (Gα) subun... |
|
2016
|
Invention
|
Oxime compounds as agonists of the muscarinic m1 and/or m4 receptor. This invention relates to co... |
|
|
Invention
|
Cgrp receptor antagonists. The disclosures herein relate to novel compounds of formula (I) wherei... |
|
|
Invention
|
Cgrp receptor antagonists. The disclosures herein relate to heterocyclic calcitonin gene-related ... |
|
|
Invention
|
Muscarinic agonists. This invention relates to compounds that are agonists of the muscarinic M1 r... |
|
|
Invention
|
Muscarinic agonists. This invention relates to compounds that are agonists of the muscarinic M4 r... |
|
|
Invention
|
Muscarinic agonists. This invention relates to compounds that are agonists of the muscarinic rece... |
|
|
Invention
|
Spirocyclic compounds as agonists of the muscarinic m1 receptor and/or m4 receptor. This inventio... |
